The incidence of factorVIIIinhibitors in severe haemophilia A following a major switch from full‐length to B‐domain‐deleted factorVIII: a prospective cohort comparison-Reference-Cited by-同舟云学术

The incidence of factorVIIIinhibitors in severe haemophilia A following a major switch from full‐length to B‐domain‐deleted factorVIII: a prospective cohort comparison

Published:2014-11-07 Issue:2 Volume:21 Page:219-226
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Hay C. R. M.¹,Palmer B. P.²,Chalmers E. A.³,Hart D. P.⁴,Liesner R.⁵,Rangarajan S.⁶,Talks K.⁷,Williams M.⁸,Collins P. W.⁹,

Affiliation:

1. Manchester University Department of Haematology Manchester Royal Infirmary Manchester UK

2. The UK National Haemophilia Database Manchester UK

3. The Department of Haematology Royal Hospital for Sick Children Glasgow UK

4. The Department of Haematology Barts and The London School of Medicine and Dentistry, QMUL London UK

5. The Haemophilia Centre Great Ormond Street Hospital London UK

6. The Haemophilia Centre Guys and St Thomas's Hospital London UK

7. The Department of Haematology Newcastle upon Tyne Hospitals NHS Trust Newcastle upon Tyne UK

8. The Department of Haematology Birmingham Children's Hospital Birmingham UK

9. The University Department of Haematology The University Hospital of Wales School of Medicine Cardiff University Cardiff UK

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.12563

Reference24 articles.

1. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation

2. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition)

3. Switching between full length and B‐domain‐deleted recombinant factor VIII and the risk of inhibitors;Keeling D;Haemophilia,2005

4. Factor VIII inhibitors development following introduction of B-domain-deleted recombinant factor VIII in four hemophilia A previously treated patients

5. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurised factor VIII concentrate;Peerlinck K;Thromb Haemost,1993

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Race, ethnicity, F8 variants, and inhibitor risk: analysis of the “My Life Our Future” hemophilia A database;Journal of Thrombosis and Haemostasis;2023-04

2. Real pandemic world results of pharmacokinetic-tailored personalized prophylaxis of bleeds in Polish children and adolescents with severe hemophilia A;Frontiers in Pediatrics;2023-02-23

3. Occurrence of FVIII Inhibitors in Hemophilia A Patients Following an Institutional Switch to a Third Generation B-Domain-Deleted FVIII;Clinical and Applied Thrombosis/Hemostasis;2023-01

4. Anti-FVIII antibodies in Black and White hemophilia A subjects: do F8 haplotypes play a role?;Blood Advances;2022-12-02

5. Intraosseous delivery of platelet-targeted factor VIII lentiviral vector in humanized NBSGW mice;Blood Advances;2022-10-11